Company intelligence / Profile preview

Optimer Pharmaceuticals, Inc.

Jersey City, New Jersey, United Statesoptimerpharma.com ↗

Ownership: Private
Development stage: Other

Overview

Optimer Pharmaceuticals developed and commercialized DIFICID (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea in adults in the United States and Canada. The company was acquired by Cubist Pharmaceuticals in 2013.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Partnerships

Astellas Pharma Europe Ltd.Par Pharmaceuticals, Inc.Cempra, Inc.Optimer Biotechnology, Inc.Scripps Research Institute

Beyond the preview

Go deeper on Optimer Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optimer Pharmaceuticals, Inc..